Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Innocoll Pharmaceuticals Limited

    Client Virtual Booth

    INNOCOLL PHARMACEUTICALS LIMITED

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Innocoll Pharmaceuticals Limited
    Ireland Flag
    Country
    Country
    Ireland
    Address
    Address
    Unit 9, Block D, Monksland Business Park, Monksland, Athlone, Co. Roscommon
    Telephone
    Telephone
    +353 (0) 90 6486834
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.innocoll.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/innocoll
    Twitter
    Twitter
    https://twitter.com/innocoll

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Innocoll and DURECT Announce U.S. launch of POSIMIR®
    Innocoll and DURECT Announce U.S. launch of POSIMIR®

    https://www.prnewswire.com/news-releases/innocoll-and-durect-announce-us-launch-of-posimir-301632764.html

    PRNEWSWIRE
    26 Sep 2022
    Share Share
    Innocoll to Publish Positive Results from Pivotal Clinical Trial of POSIMIR
    Innocoll to Publish Positive Results from Pivotal Clinical Trial of POSIMIR

    https://www.businesswire.com/news/home/20220706005105/en

    BUSINESSWIRE
    06 Jul 2022
    Share Share
    Innocoll Shows Positive Topline Results For XARACOLL implant in Phase 3 Study
    Innocoll Shows Positive Topline Results For XARACOLL implant in Phase 3 Study

    https://www.businesswire.com/news/home/20220302005437/en

    BUSINESSWIRE
    02 Mar 2022
    Share Share
    Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI)
    Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI)

    https://www.prnewswire.com/news-releases/innocoll-announces-commercial-launch-of-xaracoll-bupivacaine-hci-implant-a-non-opioid-drug-device-treatment-option-for-acute-postsurgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults-301163002.html

    PRNEWSWIRE
    29 Oct 2020
    Share Share
    Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI)
    Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI)

    https://www.prnewswire.com/news-releases/innocoll-announces-commercial-launch-of-xaracoll-bupivacaine-hci-implant-a-non-opioid-drug-device-treatment-option-for-acute-postsurgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults-301163002.html

    PRNEWSWIRE
    29 Oct 2020
    Share Share
    FDA Approves XARACOLL® (bupivacaine HCl), a Non-opioid, Drug-device Treatment
    FDA Approves XARACOLL® (bupivacaine HCl), a Non-opioid, Drug-device Treatment

    https://www.biospace.com/article/releases/fda-approves-xaracoll-bupivacaine-hcl-implant-a-non-opioid-drug-device-treatment-option-for-acute-postsurgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults/?s=74

    BIOSPACE
    31 Aug 2020
    Share Share
    Innocoll Holdings Announces FDA Acceptance ofnda for XARACOLL®
    Innocoll Holdings Announces FDA Acceptance ofnda for XARACOLL®

    https://www.prnewswire.com/news-releases/innocoll-holdings-limited-announces-fda-acceptance-of-new-drug-application-for-xaracoll-for-the-management-of-postsurgical-pain-after-open-inguinal-hernia-surgery-301030493.html

    PR NEWSWIRE
    27 Mar 2020
    Share Share
    Innocoll Holdings Announces FDA Acceptance of New Drug Application for XARACOLL®
    Innocoll Holdings Announces FDA Acceptance of New Drug Application for XARACOLL®

    https://www.prnewswire.com/news-releases/innocoll-holdings-limited-announces-fda-acceptance-of-new-drug-application-for-xaracoll-for-the-management-of-postsurgical-pain-after-open-inguinal-hernia-surgery-301030493.html

    PRNEWSWIRE
    26 Mar 2020
    Share Share
    Innocoll Holdings Resubmits NDA to FDA for XARACOLL®
    Innocoll Holdings Resubmits NDA to FDA for XARACOLL®

    https://www.prnewswire.com/news-releases/innocoll-holdings-limited-resubmits-new-drug-application-to-fda-for-xaracoll-for-the-management-of-postsurgical-pain-after-open-inguinal-hernia-surgery-301012890.html

    PR NEWSWIRE
    27 Feb 2020
    Share Share
    Innocoll Receives Refusal to File Letter from USFDA for Xaracoll NDA
    Innocoll Receives Refusal to File Letter from USFDA for Xaracoll NDA

    https://globenewswire.com/news-release/2016/12/29/902225/0/en/Innocoll-Receives-Refusal-to-File-Letter-from-U-S-FDA-for-XARACOLL-bupivacaine-HCl-collagen-matrix-implants-New-Drug-Application.html

    GLOBENEWSWIRE
    29 Dec 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search